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BACKGROUND AND PURPOSE: MR imaging may help in predicting hemorrhagic transfor-
mation (HT) in acute ischemic stroke. Our purpose was to determine whether the lesion
volumes on diffusion-weighted (DW) imaging, apparent diffusion coefficient (ADC) values, and
early parenchymal enhancement are predictive of HT and to investigate the mechanism of the
enhancement.
METHODS: We retrospectively examined 55 patients with acute ischemic stroke who under-
went gadolinium-enhanced MR imaging within 6 hours of symptom onset and follow-up CT or
MR imaging within 72 hours. Intravenous thrombolysis was performed in 15 patients. DW
imaging lesion volumes and ADC values were compared between patients with and those
without HT. ADCs and perfusion parameters were compared between lesions with and those
without parenchymal enhancement.
RESULTS: Nineteen (34.5%) patients had HT (14 with hemorrhagic infarction, five with
parenchymal hematoma). Patients with HT had decreased mean ADCs and large lesion volumes
on DW imaging, but differences were not significant (P > .05). HT occurred in five patients
(100%) with parenchymal enhancement, which corresponded to the site of HT. In enhancing
lesions, the ADC ratio (0.76  0.06) was slightly higher and the delay in time to peak (0.10 
2.79) was less than respective values in the rest of the ischemic lesion (0.66  0.06 and 8.79 
4.86, respectively; P  .068).
CONCLUSION: Early parenchymal enhancement is highly specific for HT and may be
associated with early reperfusion and damage to the blood-brain barrier in ischemic tissue. DW
imaging lesion volumes and ADC values had no strong relationship with HT.
Intravenous recombinant tissue-type plasminogen ac-
tivator (r-tPA) or intra-arterial thrombolytic therapy
substantially improves patients’ neurologic outcomes
but increases intracerebral hemorrhage (1–5). There-
fore, the identification of risk factors leading to hem-
orrhage is crucial for effective and safe thrombolytic
therapy. Various clinical risk factors for hemorrhagic
transformation (HT) in acute ischemic stroke have
been documented (4–11). In the European Cooper-
ative Acute Stroke Study I trial, the large extent of
hypoattenuation on CT was established as a predic-
tive factor for symptomatic hemorrhage and for the
poor outcome after intravenous r-tPA thrombolytic
therapy (12). However, this finding remains contro-
versial in patients treated within 3 hours (11, 13). Low
apparent diffusion coefficient (ADC) values, old mi-
crobleeds, and early parenchymal enhancement have
been suggested as potential MR imaging predictors of
hemorrhage (14–23). Reports suggest that stroke MR
imaging may be useful in identifying risk factors of
hemorrhage that may not be identified on CT. Re-
sults of several animal studies suggest that early pa-
renchymal enhancement is observed after reperfusion
and that it may enable early prediction of HT (20–
22). In their study, Vo et al (23) suggested that the
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early parenchymal enhancement may be a good pre-
dictor of symptomatic HT in patients with acute isch-
emic stroke. However, to our knowledge, the value of
various MR imaging features for the prediction of
hemorrhage has not been established in acute isch-
emic stroke.
The purpose of this study was to determine
whether lesion volume on diffusion-weighted imaging
(DW), ADC values, and early parenchymal enhance-
ment are predictive of HT in acute ischemic stroke
and to investigate the mechanism of early parenchy-
mal enhancement.
Methods
Patient Selection
Reviewing the medical records, we retrospectively selected
415 patients who presented within 6 hours after the onset of
acute ischemia between February 1997 and August 2003. We
enrolled 55 who met the following criteria: (1) confirmed acute
infarction of the middle cerebral artery (MCA) territory; (2)
MR imaging, including gadolinium-enhanced T1-weighted and
DW imaging, within 6 hours of symptom onset; and (3) fol-
low-up nonenhanced CT or MR imaging, with conventional
gradient-echo (GRE) or echo-planar gradient-echo imaging
(EPI-GRE), within 72 hours. If indicated, intravenous rt-PA
0.9 mg/kg (alteplase, maximum of 90 mg) was administered by
infusing 10% as a bolus followed by a constant infusion of the
remaining 90% for 60 minutes between the initial nonenhanced
CT and MR imaging studies.
Imaging Methods
CT scans were obtained before MR imaging in all patients.
MR images were obtained with a 1.5-T unit (Signa; GE Med-
ical Systems, Milwaukee, WI). The typical stroke-imaging pro-
tocol included DW imaging, perfusion-weighted imaging
(PWI), T2*-weighted GRE imaging, and Gd-enhanced T1-
weighted imaging, and time-of-flight MR angiography of the
intracranial arteries. DW imaging was performed with 20 sec-
tions and b values of 0 and 900 or 1000 s/mm2. Averaged DW
images were generated online by averaging three orthogonal-
axis images. Imaging parameters for DW imaging were as
follows: TR/TE 6500/96.8, matrix 128 128, FOV 24
24 or 28  28 cm, section thickness  5 mm, and intersection
gap  2 mm. In all patients, enhanced axial T1-weighted
images were obtained after PWI; the parameters were as fol-
lows: matrix  256  192, FOV  24  24 cm, section
thickness  5 mm, intersection gap  2 mm, and one excita-
tion. PWI was performed with EPI-GRE sequences with these
parameters: TR/TE  2000–2500/50–60, flip angle  90°,
FOV  24  24 cm, matrix 128  128, section thickness  5
mm, and intersection gap  2 mm. This sequence was per-
formed the injection of gadopentetate dimeglumine 0.2
mmol/kg (Magnevist; Schering, Berlin, Germany) at a rate of 4
mL/s with an MR imaging–compatible power injector (Spec-
tris; Medrad, Pittsburgh, PA). The bolus of contrast material
was followed by a 15-mL bolus of saline at the same injection
rate. A series of images (8–10 sections, 40–50 images per
section) was obtained before, during, and after administration
of the contrast agent. Perfusion maps of relative cerebral blood
volume (rCBV), time to peak (TTP), and relative cerebral
blood flow (rCBF) were generated offline at a workstation.
Details of the postprocessing method for perfusion maps were
described previously (24).
Data Processing and Analysis
One neuroradiologist manually drew the region of interest
(ROI) for the hyperintense lesion on each DW imaging section.
These ROIs were transferred to the ADC maps. Lesion vol-
umes on DW imaging and ADC values of voxels in the ROIs
were calculated. ADC values in each DW imaging lesion were
collected in all patients and divided patients into four groups:
250  106, 350  106, 450  106, and 550  106
mm2/s. The percentage and absolute number of voxels within
the group were obtained. The threshold for ADC values was
1.2  103 mm2/s to minimize the partial-volume effect
on CSF.
Two neuroradiologists who were blinded to the follow-up
images and clinical information independently reviewed the
MR images to determine the presence of early parenchymal
enhancement. When a discrepancy occurred, the decision was
made by a consensus. Early parenchymal enhancement was
defined as a hyperintense area on the initial Gd-enhanced
T1-weighted image, which was noted as the area of the hyper-
intense lesion on DW images. In patients with early parenchy-
mal enhancement, mean ADCs and perfusion parameters, in-
cluding TTP, rCBV, and rCBF, was obtained in the enhancing
area and in the rest of the ischemic lesion. For quantitative
ROI measurement in patients with early parenchymal enhance-
ment, enhanced T1-weighted images and PWIs were spatially
coregistered to the DW imaging (EPI T2-weighted imaging,
b  0 s/mm2) to superimpose the ROIs delineated on en-
hanced-T1 images by using SPM2 software (Wellcome Depart-
ment of Cognitive Neuroscience, www.fil.ion.ucl.ac.uk/spm/).
HT was defined and classified into four subtypes, as previ-
ously described (3, 14, 25): hemorrhagic infarct type 1, which
was small petechiae along the margins of the infarct; hemor-
rhagic infarct type 2, which was more confluent petechiae
within the infarcted area but without space-occupying effect;
parenchymal hematoma type 1, which was hematoma in less
than 30% of the infarcted area with some space-occupying
effect; and parenchymal hematoma type 2, which was hema-
toma in more than 30% of the infarcted area with substantial
space-occupying effect or any hemorrhagic lesion outside the
infarcted area. Symptomatic hemorrhage was defined as clini-
cal deterioration with a National Institutes of Health Stroke
Scale (NIHSS) score of more than 3 likely due to hemorrhage.
Two neuroradiologists identified HT by consensus on follow-up
MR images (n  47; with GRE images in 24 patients and
EPI-GRE images in 23) or CT scans (n  8) within 72 hours of
symptom onset.
Review of Clinical Data
We reviewed the patients’ clinical data: baseline neurologic
deficits, as assessed by using the NIHSS score; history of hy-
pertension; use of an antiplatelet agent (aspirin) or an antico-
agulant (warfarin); cardioembolic stroke risk factors, such as
atrial fibrillation; and history of diabetes.
Statistical Analysis
Statistical analysis was performed by using commercially
available software (SPSS-PC, version 10.0, 1999; SPSS, Chi-
cago, IL). Patients were divided into two groups according to
the presence or absence of HT. Differences in MR imaging
variables between the groups were assessed by using the Stu-
dent t test for continuous variables. Nominal clinical variables
between the groups were compared by using 2 test. Diffusion
and perfusion parameters in the ischemic lesion were com-
pared between lesions with and those without early parenchy-
mal enhancement by using the Wilcoxon signed ranks test. A P
value less than .05 was considered to indicate a statistically
significant difference.
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Results
Fifty-five patients (29 men, 26 women; mean age,
68.8  10.8 years; age range, 50–91 years) were se-
lected. The mean interval from the onset of their symp-
toms to MR imaging was 4.4  1.0 hours, with a range
of 2.2–6.0 hours. The mean time to follow-up imaging
was 1.27  0.2 days, ranging from 1 to 3 days. Intrave-
nous r-tPA therapy was performed in 15 patients after
MR imaging. HT was identified in 19 patients (34.5%)
at follow-up: hemorrhagic infarct in 14 patients and
parenchymal hematoma in five. Symptomatic hemor-
rhage was observed in one patient.
Table 1 summarizes the results of MR imaging.
Compared with patients without HT, patients with
HT had a lower mean ADC, a larger lesion volume on
DW imaging, and more voxels with low ADC. How-
ever, the difference was not significant (P  .05).
Similarly, among the 15 patients treated with r-tPA,
those with HT had larger DW imaging lesion volumes
and lower ADC values than those of patients without
HT. However, the differences for the DW imaging
variables were not significant (P  .05).
Early parenchymal enhancement was observed in
five patients (9%). All patients with this enhancement
had HT on follow-up imaging. Two received intrave-
nous r-tPA therapy and had a parenchymal hema-
toma type 1 or a hemorrhagic infarct type 1 in the left
basal ganglia. The others had a parenchymal hema-
toma type 1, hemorrhagic infarct type 2, or hemor-
rhagic infarct type 1 in the left parietal lobe, left
frontal lobe, and left basal ganglia, respectively. No
early parenchymal enhancement was identified in the
patients without HT (P  .003). The HT sites corre-
sponded to those with parenchymal enhancement in
all patients. No symptomatic HT developed in pa-
tients with early parenchymal enhancement.
Diffusion and perfusion parameters of the enhanc-
ing lesion were quantitatively analyzed in four pa-
tients with early parenchymal enhancement in whom
PWI was available (Table 2). Mean ADC values and
ADC ratios of enhancing lesions were slightly higher
than values in the rest of the ischemic lesion, but the
difference was not significant (P  .068 and P  .066,
respectively). The mean TTP delay was lower in lesions
with early parenchymal enhancement than in lesions
without enhancement (P  .068). Although the perfu-
sion parameters did not significantly differ between the
groups, the lesion with early parenchymal enhancement
had a TTP delay of less than 2 seconds, an increased
rCBV (ratio 1.19), and an increased rCBF (ratio
1.16) in three of four patients.
The mean initial NIHSS score of 55 patients was
15.0  5.6. In patients with HT, the score was 13.2 
6.1, and in patients without HT, it was 9.8  5.7 (P 
.043). Subsequent HT was noted in the following
patients: 12 of 30 with hypertension (P  .05), in six
of 14 receiving an anticoagulant or an antiplatelet
agent (in three of six taking warfarin and in three of
eight taking aspirin, P  .05), in 12 of 24 with atrial
fibrillation (P  .047), and in 10 of 22 with a history
of diabetes (P  .05).
TABLE 2: ADC and perfusion parameters of four enhancing lesions
Variable Enhancing Lesions Nonenhancing Lesions P Value
DWI signal intensity ratio 1.49  0.33 1.98  0.55 .109
Mean ADC ( 106 mm2/second) 592  62 510  35 .068
ADC ratio 0.76  0.06 0.66  0.06 .066
TTP delay (second) 0.10  2.79 8.79  4.86 .068
Relative CBV 1.42  0.26 0.86  0.30 .144
Relative CBF 1.58  0.99 0.59  0.33 .068
Note.—Data are the mean  standard deviation.
TABLE 1: DWI lesion volumes, ADC values, and early parenchymal enhancement
Variable No HT (n  36) HT (n  19) P Value
DWI lesion volume (cm3) 24.2  34.7 50.9  84.4 .115
Mean ADC ( 106 mm2/second) 59  78 550  101 .107
Voxels with ADC 550  106 mm2/second
Percentage 42.5  21.6 49.2  22.1 .287
Absolute number 721.1  1077.6 2887.3  8109.1 .134
Voxels with ADC 450  106 mm2/second
Percentage 20.9  16.9 27.1  21.0 .248
Absolute number 355.6  516.4 14055.9  58466.7 .181
Voxels with ADC 350  106 mm2/second
Percentage 7.0  8.5 11.7  19.4 .239
Absolute number 128.3  230.3 910.7  2876.8 .124
Voxels with ADC 250  106 mm2/second
Percentage 1.6  2.5 5.4  16.8 .216
Absolute number 32.8  77.8 233.9  672.4 .093
Gd enhancement 0 (0) 5 (26.3) .003
Note.—Data are the mean  standard deviation or number (percentage).
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Discussion
ADC values and DW imaging lesion volumes were
not strongly associated with HT, and early parenchy-
mal enhancement was significantly associated with
HT. Early parenchymal enhancement was 29% sen-
sitive but 100% specific for the development of HT.
Clinical MR studies showed that the ADC value of
ischemic tissue was predictive of HT (14–17). Al-
though a lesion with low ADCs may have severe
ischemic damage that predisposes the patient to HT,
especially after thrombolysis, our data from a small
number of patients suggest that the ADC values
themselves are not as reliable as early parenchymal
enhancement for predicting HT. This may be because
of a fogging effect on the ADC value, as reflected by
the slightly higher mean ADC ratios found in our
patients with parenchymal enhancement. This fog-
ging effect may be the result of early vasogenic edema
with increasing T2 signal intensity 2–6 hours after
stroke, when the ADC decline has stabilized, or the
result of early reperfusion (26–29). In three of our
patients, the region with parenchymal enhancement
and less severely depressed ADC had a shortened
TTP, an increased CBV, and an increased CBF, all of
which were consistent with hyperperfusion (Fig 2).
Our finding of a correlation between parenchymal
enhancement and HT was consistent with those of
previous animal and human studies (21–23). Contrast
enhancement before treatment is predictive of the
severity of hemorrhage and has a good correlation
FIG 1. A 74-year-old man with right hemiparesis and aphasia. Intravenous r-tPA was administered after nonenhanced CT was
performed 2.5 hours after symptom onset.
A, DW image and ADC map obtained 3 hours after CT show ischemic edema in the left MCA territory. TTP, rCBV, and rCBF maps
show perfusion abnormality.
B, Gd-enhanced T1-weighted image (T1WI) shows a focal enhancing area in the left basal ganglia (arrow). Follow-up nonenhanced
CT scan (NCT) depicts a small parenchymal hematoma in the left basal ganglia that corresponds to the enhancing area.
FIG 2. A 57-year-old woman with right hemiparesis and aphasia. Intravenous r-tPA was administered after nonenhanced CT was
performed 1.5 hours after symptom onset.
A, DW image and ADC map obtained 3.7 hours after CT show ischemic edema and perfusion abnormality in the left MCA territory.
TTP and rCBF maps show reperfusion in the area of parenchymal enhancement.
B, Gd-enhanced T1-weighted image (Gd-T1WI) shows parenchymal enhancement in the left perisylvian cortex and basal ganglia
(arrowheads). Enhancing lesion in the right temporal lobe (white arrow) indicates subacute infarction. Patient had atrial fibrillation and
infarction 2 months earlier. Follow-up EPI-GRE image shows focal hemorrhage (hemorrhagic infarct type 1) in only the left basal ganglia
(black arrow). No hemorrhage is present in the rest of area of parenchymal enhancement in the left MCA territory and in right temporal
lobe on the enhanced T1-weighted image.
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with the subsequent severity of HT, as shown in an
animal study (22). In one study, two of three patients
with early parenchymal enhancement after r-tPA
treatment had symptomatic hemorrhage at follow-up
(23). Because r-tPA can aggravate the rapid break-
down of the microvascular barrier (30), early paren-
chymal enhancement might be a potential risk factor
for posttreatment symptomatic hemorrhage. In con-
trast to patients in the study by Vo et al (23), our
patients with early parenchymal enhancement did not
develop symptomatic hemorrhage after r-tPA ther-
apy; therefore, the relevance of the findings to symp-
tomatic hemorrhage remains uncertain (25, 31, 32).
Various clinical data, such as baseline NIHSS
score, history of hypertension, anticoagulant use, and
cardioembolic stroke risk factors (e.g., atrial fibrilla-
tion, history of diabetes) have been suggested as risk
factors for HT in patients with acute ischemic (4,
6–11). In our study, baseline NIHSS scores and atrial
fibrillation were significantly associated with subse-
quent HT, comparable to results of prior studies.
However, other variables were not associated, possi-
bly because of relatively small number of patients.
Although the different imaging parameters for
PWI were used, the difference of scan parameters will
not significantly affect the measured values of TTP
delay, relative CBV, or relative CBF because we mea-
sured only relative values (difference of TTP value or
ratios), and the measured values were obtained from
the fitted curve by the same postprocessing software.
This study had a couple limitations. First, we were
unable to analyze the relationship between MR im-
aging features and symptomatic hemorrhage because
of the lack of subjects with symptomatic hemorrhage.
Second, this study was retrospective and did not in-
clude treated patients who underwent MR imaging
before thrombolytic therapy. Therefore, further pro-
spective study should be conducted with a large num-
ber of patients to validate early parenchymal en-
hancement as a valuable predictor of HT and to
determine the clinical importance of early parenchy-
mal enhancement in terms of thrombolytic therapy in
patients with acute ischemic stroke.
Conclusion
Early parenchymal enhancement was uncommon
(9%) in patients with acute MCA infarction within 6
hours of symptom onset, but it was highly specific for
HT. This enhancement may be associated with early
reperfusion, as well as damage to the blood-brain
barrier in the ischemic tissue. DW imaging lesion
volume and ADC value were not strongly associated
with HT.
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